Leading the Way in Life Science Technologies

GEN Exclusives

More »

Best of the Web

More »
Sep 15, 2006 (Vol. 26, No. 16)


  • Interesting information
  • Registration seems silly
Serving as a gateway of information for the biotech industry in the Czech Republic, Gate2Biotech is an attractively designed collection of pages that has a lot to offer but with a curious design scheme. A few questions come to mind. First, what exactly is the aim of the site? Promotion? The About page provides no clue. Second, why does the site require login registration, which is free anyway? It would seem that the aim of the site is promoting the Czech biotech industry, but registration will restrict viewership. Third, why do clicks on some of the database links provide no data? On the plus side, the site does have a considerable amount of news, an extensive dictionary, writings in Czech and English, and enough miscellaneous offerings to keep one busy for a while. All of these are worth viewing. Besides, how many biotech industries do you know that date their history back to the Middle Ages?
  • Key:
  • Strong Points
  • Weak Points
  • Ratings:
  • Excellent
  • Very Good
  • Good

*The opinions expressed are solely those of the author(s) and should not be construed as reflecting the viewpoints of the publisher, Genetic Engineering & Biotechnology News, Mary Ann Liebert, Inc., the publishing house, or employees and affiliates thereof.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »